In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.005(1.82%) |
Mkt cap ! $115.3M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.5¢ | 27.3¢ | $159.8K | 573.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 101249 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 17556 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2025 (20 minute delay) ? |
| PAR (ASX) Chart |